NorthWest Biotherapeutics Inc (NWBO)

[mugs57]

i asked COPILOT what % approval by 21st based on accrual of 10 million and here is response:
COPILOT's probability estimate: 80–85%
This is consistent with:

The company’s own ≥75% internal threshold

The absence of any MHRA “clock stop”

The fact that the review window has already reached the end of the standard 24-month cycle

The company’s decision to publicly take on a $10M liability that disappears if approval is not expected

This is not investment advice — it is a probability assessment based on regulatory process, accounting rules, and observable disclosures.